Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 - CDDP therapy

ABSTRACT: Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 - CDDP therapy

PROVIDER: PRJNA797652 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Human bladder cancer cell line high throughput sequencing

Project description:Human bladder cancer cell line high throughput sequencing

| PRJNA723863 | ENA

Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2

Project description:Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2

| PRJNA797648 | ENA

miR-200b is associated with cisplatin sensitivity in bladder cancer cells

Project description:We aimed to clarify the role of miR-200b in cisplatin (CDDP) sensitivity in bladder cancer (BCa). CDDP resistant T24 cells (T24RC) were transfected with a miR mimic negative control (NC) or a miR-200b mimic, after which cells were treated with or without CDDP. We found that ectopic miR-200b expression re-sensitized the T24RC cells to CDDP. Gene expression microarray analysis revealed that the combination of miR-200b and CDDP affected genes involved in CDDP sensitivity and cytotoxicity.

2018-05-31 | GSE103250 | GEO

Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 - untreated

Project description:Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 - untreated

| PRJNA797651 | ENA

Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer

Project description:Background: Bladder-sparing trimodality therapy (TMT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC), and biomarkers to inform therapy selection are needed. Objective: To evaluate immune and stromal signatures in MIBC treated with TMT.

2019-03-23 | GSE128701 | GEO

The transcriptional response of ovarian cancer cells to treatment with cisplatin (CDDP)

2013-12-31 | GSE38545 | GEO

The transcriptional response of ovarian cancer cells to treatment with cisplatin (CDDP)

Project description:The transcriptional response to CDDP of three ovarian cancer cell lines was studied. These lines show different genetic profiles and display different susceptibilities to CDDP. The time and doses that resulted in the apoptotic death of each cell line was identified and used to study the expression profiles associated to CDDP-induced cell death in each cell line. CDDP: cis-diamminedichloroplatinum(II) In order to elucidate the mechanism of CDDP dependent cell susceptibilities to drugs, the transcriptional response of the three ovarian cancer cell lines to CDDP were studied by microarray based transcription profiling

2013-12-31 | E-GEOD-38545 | biostudies-arrayexpress

Human bladder cancer cell line high throughput sequencing

Project description:Circular RNAs (circRNAs) have been increasingly indicated to be important participants in the development and progression of various malignant tumors. In this study, we analyzed circRNA high-throughout sequencing from human bladder cancer tissues and paired adjacent normal tissues. Then we focused on the upregulated circRNAs and identified a novel circular RNA, hsa_circ_0008399 , as a new candidate circRNA derived from RBM2 gene. FISH assay has been proved that hsa_circ_0008399 mainly located in nucleus. Transcriptome analysis was performed to find the potential genes that could be regulated by hsa_circ_0008399.

2022-04-13 | GSE173132 | GEO

Cdk4-inhibitor induces tumor regression of Bladder cancer in vivo using a metastatic mouse model

Project description:Cdk4/6 inhibitors have shown to increase overall survival in hormone-positive breast tumors, but whether other solid tumors could respond to these inhibitors has not yet defined. Here we show that Palbociclib (a Cdk4/6 specific inhibitor in clinic use) + cisplatin (CDDP, a chemotherapeutic agent most active in locally or advanced bladder cancer patients) treatment exerts antiproliferative effects in vivo using a bladder cancer mouse model.

2018-10-21 | GSE100716 | GEO

CDDP Lung - University of Iowa

Project description:CDDP Lung - University of Iowa

| PRJNA510155 | ENA